195 related articles for article (PubMed ID: 26558759)
1. ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.
Priori R; Casadei L; Valerio M; Scrivo R; Valesini G; Manetti C
PLoS One; 2015; 10(11):e0138537. PubMed ID: 26558759
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.
Blaschke S; Rinke K; Maring M; Flad T; Patschan S; Jahn O; Mueller CA; Mueller GA; Dihazi H
Arthritis Res Ther; 2015 Mar; 17(1):45. PubMed ID: 25884688
[TBL] [Abstract][Full Text] [Related]
3. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.
Jamnitski A; Visman IM; Peters MJ; Dijkmans BA; Voskuyl AE; Nurmohamed MT
Ann Rheum Dis; 2010 Nov; 69(11):1929-33. PubMed ID: 20498216
[TBL] [Abstract][Full Text] [Related]
5. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
Jamnitski A; Krieckaert CL; Nurmohamed MT; Hart MH; Dijkmans BA; Aarden L; Voskuyl AE; Wolbink GJ
Ann Rheum Dis; 2012 Jan; 71(1):88-91. PubMed ID: 21914626
[TBL] [Abstract][Full Text] [Related]
6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.
Cuppen BV; Fu J; van Wietmarschen HA; Harms AC; Koval S; Marijnissen AC; Peeters JJ; Bijlsma JW; Tekstra J; van Laar JM; Hankemeier T; Lafeber FP; van der Greef J;
PLoS One; 2016; 11(9):e0163087. PubMed ID: 27631111
[TBL] [Abstract][Full Text] [Related]
8. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
[TBL] [Abstract][Full Text] [Related]
9. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study.
Murillo-Saich JD; Diaz-Torne C; Ortiz MA; Coras R; Gil-Alabarse P; Pedersen A; Corominas H; Vidal S; Guma M
Metabolomics; 2021 Aug; 17(9):74. PubMed ID: 34402961
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
12. Onset of action of etanercept in rheumatoid arthritis based on patient-reported outcomes.
Dougados M; Ripert M; Hilliquin P; Brocq O; Brault Y; Logeart I
Clin Exp Rheumatol; 2012; 30(2):266-8. PubMed ID: 22325048
[TBL] [Abstract][Full Text] [Related]
13. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
[TBL] [Abstract][Full Text] [Related]
14. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
15. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
[TBL] [Abstract][Full Text] [Related]
16. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A
Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261
[TBL] [Abstract][Full Text] [Related]
17. Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response.
Obry A; Hardouin J; Lequerré T; Jarnier F; Boyer O; Fardellone P; Philippe P; Marcelli C; Loët XL; Vittecoq O; Cosette P
Theranostics; 2015; 5(11):1214-24. PubMed ID: 26379787
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis.
Dudka I; Chachaj A; Sebastian A; Tański W; Stenlund H; Gröbner G; Szuba A
J Pharm Biomed Anal; 2021 Apr; 197():113971. PubMed ID: 33639525
[TBL] [Abstract][Full Text] [Related]
19. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
